[Chemoradiotherapy for muscle-invasive cancer: methods, surveillance and results. An update from the cancer committee of the French National Association of Urology].

Date publication

janvier 2012

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROY Catherine

Tous les auteurs :
Quintens H, Roupret M, Larre S, Neuzillet Y, Pignot G, Comperat E, Wallerand H, Houede N, Roy C, Soulie M, Pfister C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22196000

Résumé

Radical cystectomy is the treatment of choice for non-metastatic, muscle infiltrating bladder cancer. However, bladder-sparing approaches can be discussed in carefully selected patients. Bladder-preservation protocols aim to guaranty local control and survival with a functional bladder and a good quality of life. The ideal candidate for bladder-preservation therapy is a patient with a small tumor, stage T2, in whom a complete trans-urethral resection of the bladder tumor is achievable, who has no associated carcinoma in situ or hydronephrosis, and who is medically fit to receive chemotherapy. The 5- and 10-year survival rates for muscle-invasive tumors are approximately 50% and 35%, comparable to the results achievable with cystectomy. Approximately 80% of long-term survivors will preserve a native bladder, and approximately 75% of them will have a normal-functioning bladder.

Référence

Prog Urol. 2012 Jan;22(1):13-6